Type 1 diabetes trials in Qatar

1 trial · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

• Phase 4Not yet taking people in Qatar
  Can the Addition of Pioglitazone to SGLT2 Inhibitor in Type 1 Diabetic Patients Amplify the Decrease in HbA1c and Prevent the Increase in Plasma Ketone Concentration?

  Where

  Doha

  Age

  18 years and over

  People

  60 worldwide

  Run by

  Dasman Diabetes Institute

  See details and how to joinNCT06922656